Bridging Cancer Research and Clinical Care

Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Cancer Care Alliance are bridging laboratory sciences and patient care to provide the most precise treatment options for patients with cancer. Patients world-wide are benefiting from these efforts.

Collectively, these leading cancer research and clinical care organizations are enhancing our knowledge of cancer using population research, preclinical cancer biology, translational, imaging and clinical studies of solid tumors and hematologic cancers.

Seattle Translational Tumor Research (STTR) creates environments which enable researchers and clinicians to accelerate scientific discovery and translate it into cures for patients; and has established programs addressing a number of cancers: anogenital, bladder, brain, breast, colon, head and neck, leukemia, lymphoma, myelodysplastic/myeloproliferative disease, lung, myeloma, ovary, pancreas, prostate and sarcoma.


Arriving in June - Oncoscape verison 3

Oncoscape is designed to create a collaborative platform and community that unites the clinical, genetic, and computational fields in an effort to advance the understanding of cancer biology and improve patient care. We believe that computers can revolutionize cancer research, and we are making direct efforts to connect the entire pipeline in translational medicine, reduce duplicative efforts, and create a mechanism for sharing cross-disciplinary research and developments.

Explore. Analyze. Learn.

  • Public & Private Datasets
    Securely upload and analyze your genomic, event and clinical data or select from our growing collection of public data sets.
  • Best-in-class workflows
    Quickly make sense of your data with highly visual analyses backed by industry standard libraries including: Sci-Kit Learn, Timelines and DESeq2.
  • Reproducibility
    Capture and replay your analysis with step-wise interrogation of data and methods.

Interested in learning more? Visit our webpage, or contact our Oncoscape team.

We would like to hear from you or share our newsletter with you.  Send us your questions or comments or subscribe to our newsletter.